Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …

Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …

Importance Except for ocrelizumab, treatment options in primary progressive multiple
sclerosis (PPMS) are lacking. Objective To investigate the effectiveness of DMTs on the risk …

Multiple sclerosis (MS) is an autoimmune chronic inflammatory disease with distinctive
features of focal demyelination, axonal loss, activation of glial cells, and immune cells …

Multiple sclerosis (MS) presenting in the pediatric years can lead to landmark disability
levels younger in life than adult onset MS and so therefore early and effective treatment …

The use of monoclonal antibodies in multiple sclerosis (MS) patients is in a transitional
period. Studies regarding well-established, effective antibodies such as natalizumab and …

Objectives The rapid expansion in treatment options for relapsing-remitting multiple
sclerosis (RRMS) of the past decade requires clinical decision making on the sequential …

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that
affects nearly 2.8 million people each year. MS distinguishes three main types: relapsing …

Objectives Most patients with multiple sclerosis (MS) switch between disease-modifying
therapies (DMTs) during their lifetime. Our aim was to develop an MS cost-utility model that …

Aim: To develop a microsimulation model to assess the potential health economic impact of
software-assisted MRI in detecting disease activity or progression in relapsing-remitting …